Viken – September 19, 2023 – Today, Swedish biopharmaceutical company TikoMed AB announced the formation of its Scientific Advisory Board (SAB).
The SAB will work cohesively with management to advance the company’s clinical development of ILB, TikoMeds drug in Phase 2 development in ALS. The board will integrate highly experienced clinicians as well as seasoned industrial scientific leaders in the field.
The first member to be announced is Dr. Merit Cudkowicz. Dr. Merit Cudkowicz is the Director of the Sean M. Healey & AMG Center for ALS, Chair of Neurology at Mass General, and the Julieanne Dorn Professor of Neurology at Harvard Medical School.
“We are excited to welcome Dr. Cudkowicz to join our SAB,” said Adam Bruce, Founder, Chairman of the Board and CEO, of TikoMed. “Merit, is a world renowned clinical and scientific thought leader. She can provide TikoMed with relevant and informed counsel in the months and years ahead, as we further our clinical efforts.
“I feel very enthusiastic about joining the TikoMed SAB and I looking forward to contributing my experience to the upcoming clinical study”, says Dr Merit Cudkowicz
Merit Cudkowicz, MD, MSC
- Dr. Merit Cudkowicz is the Director of the Sean M. Healey & AMG Center for ALS, Chairof Neurology at Mass General, and the Julieanne Dorn Professor of Neurology at Harvard Medical School. Dr. Cudkowicz’s research and clinical activities are dedicated to the study and treatment of people with Amyotrophic Lateral Sclerosis (ALS). Dr. Cudkowicz is one of the founders and past Co-Chairs of the Northeast ALS Consortium (NEALS), a group of over
145 clinical sites in the United States, Canada, Europe and the Middle East dedicated to performing collaborative clinical trials and research in ALS. She has brought innovations to accelerate the development of treatments for people with ALS rapidly. - Dr. Cudkowicz is Principal Investigator of the Clinical Coordination Center for the National Institute of Neurological Disorders and Stroke’s Neurology Network of Excellence in Clinical Trials (NeuroNEXT). Dr. Cudkowicz is launching the first platform trial initiative in ALS, the HEALEY ALS Platform Trial, a program that will greatly accelerate therapy development in ALS.
Dr. Cudkowicz received the American Academy of Neurology 2009 Sheila Essay ALS award, the 2017 Forbes Norris Award from the International MND Alliance, the 2017 Pinnacle Award from the Boston Chamber of Commerce and the 2019 Ray Adams American Neurological Association Award. A dedicated educator, Dr. Cudkowicz mentors many young neurologists in clinical investigation of ALS and related neurodegenerative disorders. Dr. Cudkowicz completed her undergraduate degree in chemical engineering at Massachusetts Institute of Technology and obtained a medical degree in the Health Science and Technology program of Harvard Medical School. She served her internship at Beth Israel Hospital in New York and her neurology residency and fellowship at MGH. She also obtained a master’s degree in Clinical Epidemiology from the Harvard School of Public Health.
Contact
Adam Bruce, Founder, Chairman of the Board and CEO of Tikomed
Email: adam.bruce@tikomed.com.
About TikoMed AB
TikoMed is committed to improve human life by exploring and harnessing the medical potential of the body’s ability to self-repair and regenerate. With an adaptive, multi-modal mechanism of action, TikoMed’s drug platform has the potential to rebalance the body’s inflammatory, immune and fibrotic responses to acute and chronic inflammation to enhance self-repair and regeneration.
TikoMed’s initial development programs include Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI) and islet cell transplantation.
TikoMed’s highly scalable proprietary technology aims to provide safe, qualitative and affordable medicine to as many patients as possible across the globe.
TikoMed is privately-owned and based in Viken, Sweden. To learn more, visit www.tikomed.com